Publication:
International Consensus on Differential Diagnosis and Management of Patients With Danon Disease: JACC State-of-the-Art Review.

dc.contributor.authorHong, Kimberly N
dc.contributor.authorEshraghian, Emily A
dc.contributor.authorArad, Michael
dc.contributor.authorArgirò, Alessia
dc.contributor.authorBrambatti, Michela
dc.contributor.authorBui, Quan
dc.contributor.authorCaspi, Oren
dc.contributor.authorde Frutos, Fernando
dc.contributor.authorGreenberg, Barry
dc.contributor.authorHo, Carolyn Y
dc.contributor.authorKaski, Juan Pablo
dc.contributor.authorOlivotto, Iacopo
dc.contributor.authorTaylor, Matthew R G
dc.contributor.authorYesso, Abigail
dc.contributor.authorGarcia-Pavia, Pablo
dc.contributor.authorAdler, Eric D
dc.date.accessioned2024-05-10T08:34:27Z
dc.date.available2024-05-10T08:34:27Z
dc.date.issued2023-10-17
dc.description.abstractDanon disease is a rare X-linked autophagic vacuolar cardioskeletal myopathy associated with severe heart failure that can be accompanied with extracardiac neurologic, skeletal, and ophthalmologic manifestations. It is caused by loss of function variants in the LAMP2 gene and is among the most severe and penetrant of the genetic cardiomyopathies. Most patients with Danon disease will experience symptomatic heart failure. Male individuals generally present earlier than women and die of either heart failure or arrhythmia or receive a heart transplant by the third decade of life. Herein, the authors review the differential diagnosis of Danon disease, diagnostic criteria, natural history, management recommendations, and recent advances in treatment of this increasingly recognized and extremely morbid cardiomyopathy.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis paper represents the consensus opinions of the authors, borne from an International Advisory Board meeting funded by Rocket Pharmaceuticals, who also provided support for development of the Central Illustration. Dr Garcia-Pavia has received consulting fees from Lexeo Therapeutics and Rocket Pharmaceuticals. Dr Adler has served as Chief Science Officer for Lexeo Therapeutics; and has served as an advisor for Rocket Pharmaceuticals.es_ES
dc.format.number16es_ES
dc.format.page1628es_ES
dc.format.volume82es_ES
dc.identifier.citationJ Am Coll Cardiol. 2023 Oct 17;82(16):1628-1647.es_ES
dc.identifier.doi10.1016/j.jacc.2023.08.014es_ES
dc.identifier.e-issn1558-3597es_ES
dc.identifier.journalJournal of the American College of Cardiologyes_ES
dc.identifier.pubmedID37821174es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19344
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.publisherversion10.1016/j.jacc.2023.08.014es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Miocardiopatías Hereditariases_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshGlycogen Storage Disease Type IIbes_ES
dc.subject.meshCardiomyopathieses_ES
dc.subject.meshHeart Failurees_ES
dc.subject.meshHumanses_ES
dc.subject.meshMalees_ES
dc.subject.meshFemalees_ES
dc.subject.meshDiagnosis, Differentiales_ES
dc.subject.meshConsensuses_ES
dc.subject.meshLysosomal-Associated Membrane Protein 2es_ES
dc.titleInternational Consensus on Differential Diagnosis and Management of Patients With Danon Disease: JACC State-of-the-Art Review.es_ES
dc.typereview articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication52ada1ee-7241-4738-b46d-90a5ccc14894
relation.isAuthorOfPublication.latestForDiscovery52ada1ee-7241-4738-b46d-90a5ccc14894

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
International Consensus on Differential Diagnosis_J Am Coll Cardiol_2023.pdf
Size:
1.89 MB
Format:
Adobe Portable Document Format
Description:
Review